About Event

Join Us at the Largest IPF Gathering

The 6th IPF Summit is your opportunity to make meaningful connections face-to-face with experts in the field, and discuss how to overcome your current challenges to advance research and therapeutics for the 3 million patients suffering with IPF worldwide. 

Join 150+ industry pioneers with the likes of Boehringer Ingelheim, Genentech, AbbVie, Gilead, Bayer, Lung Therapeutics, Galecto, Pliant Therapeutics, and United Therapeutics, in addition to the key opinion leaders such as Fernando Martinez, Naftali Kaminski, Toby Maher, and many more.

Spanning four days packed full of unrivaled content, they will be discussing all-things-IPF; from rethinking senescence to effectively repairing and regenerating lung tissue, to leveraging synthetic control arms in placebo-controlled trials. 

Agenda at a Glance

agenda at a glance

Access the Full Event Guide for the complete speaker faculty and session details

Unmissable Highlights Include

Basic Science & Early Translational

Advancing the Understanding of the Pathology & Molecular Mechanisms of IPF to Identify Potential Targets with Matthew Thomas, Executive Director, Head of Immunology & Respiratory Diseases, Boehringer Ingelheim

 

Advancing Models that Reflect the Pharmacokinetic & Pharmacodynamic Properties of Fibrosis with Meghan Clements, Principal Scientist, AbbVie

 

Transforming IPF Targets: Turning Towards Epithelial Cells with Naftali Kaminski, Professor, Yale School of Medicine 

 

Late Translational & Clinical

Illuminating the Last 12 Months of IPF Drug Development Research with Fernando Martinez, Chief Division of Pulmonary & Critical Care, Cornell University 
  
Discussing the Latest in the PROLIFIC Consortium Biomarker Research to be Utilized in PF Clinical Trials with Peter Schafer, Scientific Vice President, Bristol Myers Squibb
  
Navigating Regulatory Expectations Using Knowledge From the Journey of IPF Therapeutics to Propel Your Therapeutic Candidates to Patients with Lydia Gilbert-McClain, Principal, LVM Pharmaceuticals Consulting (Former Regulatory Director)